CXCR2 and pancreatic ductal adenocarcinoma: Inhibition of CXCR1 and/or CXCR2 by pharmacological or genetic approaches showed that limiting neutrophil infiltration resulted in reduced tumor growth in murine models of pancreatic ductal adenocarcinoma [135], colorectal cancer [133], lung adenocarcinoma [74], and rhabdomyosarcoma [136].